Review article

https://doi.org/10.11613/BM.2017.034

Insights on glicentin, a promising peptide of the proglucagon family

Juliette Raffort ; Clinical Chemistry Laboratory, University Hospital of Nice, Nice, France
Fabien Lareyre ; Université Côte d’Azur, Institute for Research on Cancer and Aging, Nice, France
Damien Massalou ; Department of General Surgery and Digestive Cancerology, University Hospital of Nice, Nice, France
Patrick Fénichel ; Department of Endocrinology, University Hospital of Nice, Nice, France
Patricia Panaïa-Ferrari ; Clinical Chemistry Laboratory, University Hospital of Nice, Nice, France
Giulia Chinetti ; Clinical Chemistry Laboratory, University Hospital of Nice, Nice, France

Abstract

Glicentin is a proglucagon-derived peptide mainly produced in the L-intestinal cells. While the roles of other members of the proglucagon family including glucagon-like peptide 1, glucagon-like peptide 2 and oxyntomodulin has been well studied, the functions and variation of glicentin in human are not fully understood. Experimental and clinical studies have highlighted its role in both intestinal physiology and glucose metabolism, pointing to its potential interest in a wide range of pathological states including gastrointestinal and metabolic disorders. Due to its structure presenting many similarities with the other proglucagon-derived peptides, its measurement is technically challenging. The recent commercialization of specific detection methods has offered new opportunities to go further in the understanding of glicentin physiology. Here we summarize the current knowledge on glicentin biogenesis and physiological roles. In the limelight of clinical studies investigating glicentin variation in human, we discuss future directions for potential applications in clinical practice.

Keywords

glicentin; proglucagon; glucagon-like peptide; oxyntomodulin; enteroendocrine cells

Hrčak ID:

183383

URI

https://hrcak.srce.hr/183383

Publication date:

15.6.2017.

Visits: 919 *